Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Long-Term Investments: 2020-2025

Historic Long-Term Investments for Mirum Pharmaceuticals (MIRM) over the last 3 years, with Sep 2025 value amounting to $2.5 million.

  • Mirum Pharmaceuticals' Long-Term Investments fell 73.50% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year decrease of 73.50%. This contributed to the annual value of $12.5 million for FY2024, which is N/A change from last year.
  • Per Mirum Pharmaceuticals' latest filing, its Long-Term Investments stood at $2.5 million for Q3 2025, which was down 85.57% from $17.1 million recorded in Q2 2025.
  • Over the past 5 years, Mirum Pharmaceuticals' Long-Term Investments peaked at $20.9 million during Q1 2025, and registered a low of $2.5 million during Q3 2025.
  • Its 2-year average for Long-Term Investments is $13.2 million, with a median of $14.8 million in 2024.
  • Within the past 5 years, the most significant YoY rise in Mirum Pharmaceuticals' Long-Term Investments was 0.22% (2025), while the steepest drop was 73.50% (2025).
  • Over the past 3 years, Mirum Pharmaceuticals' Long-Term Investments (Quarterly) stood at $5.0 million in 2021, then reached $12.5 million in 2024, then plummeted by 73.50% to $2.5 million in 2025.
  • Its Long-Term Investments was $2.5 million in Q3 2025, compared to $17.1 million in Q2 2025 and $20.9 million in Q1 2025.